<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-129402</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Obesity and Psoriasis: Inflammatory Nature of Obesity, Relationship Between Psoriasis and Obesity, and Therapeutic Implications</dc:title>
<dc:description xml:lang="en">Obesity, particularly abdominal obesity, is currently considered a chronic low-grade inflammatory condition that plays an active role in the development of the pathophysiologic phenomena responsible for metabolic syndrome and cardiovascular disease through the secretion of proinflammatory adipokines and cytokines. In recent years clear genetic, pathogenic, and epidemiologic links have been established between psoriasis and obesity, with important implications for health. The relationship between the 2 conditions is probably bidirectional, with obesity predisposing to psoriasis and psoriasis favoring obesity. Obesity also has important implications in the treatment of psoriasis, such as a greater risk of adverse effects with conventional systemic drugs and reduced efficacy and/or increased cost with biologic agents, for which dosage should be adjusted to the patient's weight (AU)</dc:description>
<dc:creator>Rocamora, V</dc:creator>
<dc:creator>Coll-Puigserver, N</dc:creator>
<dc:creator>Jimenez-Puya, R</dc:creator>
<dc:creator>Fonseca, E</dc:creator>
<dc:creator>Carrascosa, J. M</dc:creator>
<dc:creator>Moreno, J. C</dc:creator>
<dc:creator>Fernandez-Torres, R. M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La obesidad, en particular la abdominal, se considera en la actualidad como un proceso inflamatorio crónico de bajo grado que participa de forma activa en el desarrollo de los fenómenos fisiopatológicos responsables del síndrome metabólico y la morbilidad cardiovascular a través de la secreción de adipocinas y citocinas proinflamatorias. En los últimos años se ha establecido un vínculo firme entre psoriasis y obesidad que abarca aspectos genéticos, patogénicos y epidemiológicos, con importantes repercusiones en la salud del individuo. Es probable una relación bidireccional, en la que la obesidad predispone a la psoriasis, pero también la psoriasis favorece la obesidad. La obesidad tiene también importantes implicaciones terapéuticas, como el mayor riesgo de efectos adversos en el caso de los fármacos sistémicos convencionales y la disminución de la eficacia y/o el incremento del coste en el caso de los fármacos biológicos, que hace recomendable ajustar la dosis al peso del paciente (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;105(1): 31-44, ene.-feb. 2014. ilus</dc:source>
<dc:identifier>ibc-129402</dc:identifier>
<dc:title xml:lang="es">Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relación entre psoriasis y obesidad e implicaciones terapéuticas</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28169^s22020</dc:subject>
<dc:subject>^d28169^s22000</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12002^s22012</dc:subject>
<dc:subject>^d12002^s22067</dc:subject>
<dc:subject>^d9951^s22012</dc:subject>
<dc:subject>^d9951^s22067</dc:subject>
<dc:subject>^d12002^s22053</dc:subject>
<dc:subject>^d12002^s22032</dc:subject>
<dc:subject>^d30164^s22000</dc:subject>
<dc:subject>^d9951^s22032</dc:subject>
<dc:subject>^d9951^s22053</dc:subject>
<dc:subject>^d52657^s22031</dc:subject>
<dc:type>article</dc:type>
<dc:date>201402</dc:date>
</metadata>
</record>
</ibecs-document>
